|
|
|
|
|
|
Rheumatoid Arthritis: On behalf of a large pharmaceutical company, we assessed the commercial potential, competitive positioning, and
development path for a Phase I, small molecule therapy to be positioned between methotrexate and high-priced biological products.
Crohn's Disease: Health Advances completed a study for a mid-sized biotech company that had in-licensed technology to optimize the
glycoconjugation of drugs for improved immunomodulatory effect. Health Advances assessed the commercial potential for this technology in allergic asthma,
psoriasis, MS, Crohn's disease, rheumatoid arthritis, and inflammatory bowel disease. Crohn's disease emerged as an area of higher interest leading to a
more detailed investigation.
Serum Lupus Erythematosus: Health Advances assisted a biotech client with the evaluation of potential development options for a novel
in-licensing opportunity for use in SLE. Given the potentially broad physiological role for the drug, we narrowed in on a few potential development
targets and performed a more detailed investigation on these targets.
Lysosomal Storage Diseases: Health Advance prepared a comprehensive plan for a university-based start-up company that included an analysis of
the market opportunity, evaluation of competitors, an outline of the development and manufacturing plan, and the preparation of a two-year staffing plan.
GERD: A client with a novel device-oriented approach for treating GERD sought assistance from Health Advances in creating a valuation model.
Our client was preparing to negotiate a development partnership and license with one of the largest medical device firms. Supplementing our knowledge of
the field with interviews with gastroenterologists, we were able to give the company reliable ammunition to argue for a more attractive set of deal terms.
|
|
 |
|
|
|
|
